Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 4 Nov 2020 |
| Genmab Announces Financial Results for the First Nine Months of 2020 | 4 Nov 2020 |
| Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) | 30 Oct 2020 |
| Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis | 21 Oct 2020 |
| Genmab to Host Capital Markets Day | 15 Oct 2020 |
| Genmab A/S has published its Articles of Association | 15 Oct 2020 |